利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.063 秒)

    Methods of Treating RSV Infections And Related Conditions
    1.
    发明申请
    Methods of Treating RSV Infections And Related Conditions 审中-公开
    治疗RSV感染和相关条件的方法

    公开(公告)号：US20110008329A1

    公开(公告)日：2011-01-13

    申请号：US12600292

    申请日：2008-06-25

    申请人： Subramaniam Krishnan ,  JoAnn Suzich ,  Peter Kiener ,  Genevieve Losonsky ,  Herren Wu ,  William Dall'Acqua ,  Bettina Richter

    发明人： Subramaniam Krishnan ,  JoAnn Suzich ,  Peter Kiener ,  Genevieve Losonsky ,  Herren Wu ,  William Dall'Acqua ,  Bettina Richter

    IPC分类号： A61K39/395 ,  C07K16/10 ,  A61P31/14 ,  A61P37/04

    CPC分类号： C07K16/1027 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/77

    摘要： The present invention provides methods for managing, treating and/or ameliorating a respiratory syncytial virus (RSV) infection (e.g., acute RSV disease, or a RSV upper respiratory tract infection (URI) and/or lower respiratory tract infection (LRI)), and/or a symptom or a long-term respiratory condition relating thereto (e.g., asthma, wheezing, reactive airway disease (RAD), or chronic obstructive pulmonary disease (COPD)) in a subject, comprising administering to said human an effective amount of one or more antibodies that immunospecifically bind to one or more RSV antigens with a high affinity and/or high avidity and further comprise a modified IgG constant domain, or FcRn-binding fragment thereof, to not only decrease RSV infection, but also decrease the pro-inflammatory epithelial cell immune responses in order to mitigate the later development of asthma and/or wheezing and/or COPD in said patient.

    摘要翻译： 本发明提供了用于管理，治疗和/或改善呼吸道合胞病毒（RSV）感染（例如急性RSV疾病或RSV上呼吸道感染（URI）和/或下呼吸道感染（LRI））的方法， 和/或与受试者相关的症状或长期呼吸道状况（例如，哮喘，喘鸣，反应性气道疾病（RAD）或慢性阻塞性肺疾病（COPD））），包括向所述人施用有效量的 一种或多种以高亲和性和/或高亲合力免疫特异性结合一种或多种RSV抗原的抗体，并且还包含经修饰的IgG恒定结构域或其FcRn结合片段，以不仅降低RSV感染，而且减少pro - 炎症性上皮细胞免疫应答，以减轻所述患者中哮喘和/或喘息和/或COPD的后期发展。

    Molecules with extended half-lives, compositions and uses thereof
    4.
    发明授权
    Molecules with extended half-lives, compositions and uses thereof 有权
    具有延长半衰期，组成和用途的分子

    公开(公告)号：US07658921B2

    公开(公告)日：2010-02-09

    申请号：US11762525

    申请日：2007-06-13

    申请人： William Dall'Acqua ,  Herren Wu ,  Peter Kiener

    发明人： William Dall'Acqua ,  Herren Wu ,  Peter Kiener

    IPC分类号： A61K39/40

    CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K16/1027 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

    摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

    摘要翻译： 本发明提供了由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的IgG，非IgG免疫球蛋白，蛋白质和非蛋白质试剂的分子，其具有一个 或更多的氨基酸修饰，其增加FcRn的恒定结构域或片段的亲和力。 具有增加的半衰期的这种蛋白质和分子具有在这种分子的治疗，预防或诊断使用中需要更少量和/或更低频率给药的优点。

    High affinity antibodies against HMGB1 and methods of use thereof
    5.
    发明授权
    High affinity antibodies against HMGB1 and methods of use thereof 失效
    针对HMGB1的高亲和力抗体及其使用方法

    公开(公告)号：US07585504B2

    公开(公告)日：2009-09-08

    申请号：US11254679

    申请日：2005-10-21

    申请人： Herren Wu ,  Christian B. Allan ,  Changshou Gao ,  Ling-Ling An ,  Peter Kiener ,  Su-Yau Mao ,  Anthony Coyle

    发明人： Herren Wu ,  Christian B. Allan ,  Changshou Gao ,  Ling-Ling An ,  Peter Kiener ,  Su-Yau Mao ,  Anthony Coyle

    IPC分类号： A61K39/395

    CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30 ,  Y02A50/412

    摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

    摘要翻译： 公开了用于抑制促炎细胞因子从脊椎动物细胞中释放并抑制患者炎性细胞因子级联的组合物和方法。 组合物包含例如特异性结合HMG1的高亲和力抗体及其抗原性片段。 本发明的高亲和力抗体和包含其的药物组合物可用于许多目的，例如作为针对广泛范围的炎性疾病和病症的治疗剂，例如败血症，类风湿性关节炎，腹膜炎，克罗恩病，再灌注损伤，败血症 内毒素性休克，囊性纤维化，心内膜炎，牛皮癣，牛皮癣关节炎，关节炎，过敏性休克，器官缺血，再灌注损伤和同种异体移植排斥。 此外，本发明的高亲和力抗体可用作诊断抗体。

    Method of Identifying Membrane Ig Specific Antibodies and Use Thereof for Targeting Immunoglobulin-Producing Precursor Cells
    6.
    发明申请
    Method of Identifying Membrane Ig Specific Antibodies and Use Thereof for Targeting Immunoglobulin-Producing Precursor Cells 有权
    鉴定膜Ig特异性抗体的方法及其用途靶向免疫球蛋白产生前体细胞

    公开(公告)号：US20090130111A1

    公开(公告)日：2009-05-21

    申请号：US12067396

    申请日：2006-09-28

    申请人： Herren Wu ,  Peter Kiener ,  Partha S. Chowdhury ,  James F. Young

    发明人： Herren Wu ,  Peter Kiener ,  Partha S. Chowdhury ,  James F. Young

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C12N15/11 ,  C40B30/04 ,  C12N5/06

    CPC分类号： G01N33/56972 ,  A61K2039/505 ,  C07K16/4291 ,  C07K2317/52 ,  C07K2317/55 ,  Y10S424/805 ,  Y10S530/862 ,  Y10S530/868

    摘要： The present invention relates to the discovery of antibodies that bind to novel epitopes present on membrane-anchored immunoglobulins and which bind to these novel epitopes on the surface of B cells and plasma cells. In addition, the antibodies of the present invention can mediate ADCC and can be useful to deplete those B cells and plasma cells expressing the novel epitopes of the invention. The antibodies of the present invention can be useful for the treatment of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells. Accordingly the present invention also provides compositions and methods for the prevention, management, treatment or amelioration of B cell-mediated diseases and diseases caused by monoclonal expansion of B cells.

    摘要翻译： 本发明涉及结合存在于膜锚定的免疫球蛋白上并与B细胞和浆细胞表面上的这些新表位结合的抗体的发现。 此外，本发明的抗体可以介导ADCC，并且可用于消耗表达本发明的新表位的那些B细胞和浆细胞。 本发明的抗体可用于治疗由B细胞的单克隆扩增引起的B细胞介导的疾病和疾病。 因此，本发明还提供了用于预防，治疗或改善由B细胞的单克隆扩增引起的B细胞介导的疾病和疾病的组合物和方法。

    High affinity antibodies against HMGB1 and methods of use thereof
    7.
    发明授权
    High affinity antibodies against HMGB1 and methods of use thereof 失效
    针对HMGB1的高亲和力抗体及其使用方法

    公开(公告)号：US07964706B2

    公开(公告)日：2011-06-21

    申请号：US12094447

    申请日：2006-11-27

    申请人： Herren Wu ,  Changshou Gao ,  Ling-Ling An ,  Peter Kiener ,  Su-Yau Mao ,  Anthony Coyle ,  Jane Tian

    发明人： Herren Wu ,  Changshou Gao ,  Ling-Ling An ,  Peter Kiener ,  Su-Yau Mao ,  Anthony Coyle ,  Jane Tian

    IPC分类号： C07K16/00

    CPC分类号： C07K16/24 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/32

    摘要： Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.

    摘要翻译： 公开了用于抑制促炎细胞因子从脊椎动物细胞中释放并抑制患者炎性细胞因子级联的组合物和方法。 组合物包含例如特异性结合HMG1的高亲和力抗体及其抗原性片段。 本发明的高亲和力抗体和包含其的药物组合物可用于许多目的，例如作为针对广泛范围的炎性疾病和病症的治疗剂，例如败血症，类风湿性关节炎，腹膜炎，克罗恩病，再灌注损伤， 败血症，内毒素性休克，囊性纤维化，心内膜炎，牛皮癣，牛皮癣关节炎，关节炎，过敏性休克，器官缺血，再灌注损伤和同种异体移植排斥。 此外，本发明的高亲和力抗体可用作诊断抗体。

    Molecules with extended half-lives, compositions and uses thereof
    8.
    发明申请
    Molecules with extended half-lives, compositions and uses thereof 有权
    具有延长半衰期，组成和用途的分子

    公开(公告)号：US20080181887A1

    公开(公告)日：2008-07-31

    申请号：US11762525

    申请日：2007-06-13

    申请人： William Dall-Acqua ,  Herren Wu ,  Peter Kiener

    发明人： William Dall-Acqua ,  Herren Wu ,  Peter Kiener

    IPC分类号： A61K39/00

    CPC分类号： C07K16/00 ,  A61K2039/505 ,  C07K16/1027 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/00

    摘要： The present invention provides molecules, including IgGs, non-IgG immunoglobulin, proteins and non-protein agents, that have increased in vivo half-lives due to the presence of an IgG constant domain, or a portion thereof that binds the FcRn, having one or more amino acid modifications that increase the affinity of the constant domain or fragment for FcRn. Such proteins and molecules with increased half-lives have the advantage that smaller amounts and or less frequent dosing is required in the therapeutic, prophylactic or diagnostic use of such molecules.

    摘要翻译： 本发明提供了由于存在IgG恒定结构域或其结合FcRn的部分而具有增加的体内半衰期的IgG，非IgG免疫球蛋白，蛋白质和非蛋白质试剂的分子，其具有一个 或更多的氨基酸修饰，其增加FcRn的恒定结构域或片段的亲和力。 具有增加的半衰期的这种蛋白质和分子具有在这种分子的治疗，预防或诊断使用中需要更少量和/或更低频率给药的优点。